)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Vyome
Vyome (HIND) investor relations material
Vyome Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary18 Mar, 2026
Executive summary
Completed merger with ReShape Lifesciences Inc. in August 2025, rebranding as Vyome Holdings, Inc.; focus shifted to clinical-stage specialty pharmaceuticals targeting immune-inflammatory and rare diseases.
Lead program VT-1953 (topical gel for malignant fungating wounds) advanced with positive Phase 2 results; pivotal Phase 3 trial planned for 2026.
Additional pipeline includes VT-1908 (ophthalmic drops for uveitis, pre-IND stage) and VB-1953 (acne, Phase 3-ready).
Commercialized antifungal products in India via Sun Pharma partnership; legacy dandruff product agreement terminated in December 2024.
Financial highlights
Net loss for 2025 was $10.5 million, compared to $1.4 million in 2024, reflecting increased R&D and G&A expenses post-merger.
Revenue for 2025 was $319,714, up from $256,944 in 2024, primarily from milestone payments, royalties, and service fees from Sun Pharma.
Cash and cash equivalents at year-end 2025 were $4.98 million, with additional $5.3 million raised in early 2026.
Research and development expenses increased to $588,258 in 2025 from $285,391 in 2024 due to resumed R&D activities.
General and administrative expenses rose to $2.37 million in 2025, mainly due to merger-related costs and stock-based compensation.
Outlook and guidance
Cash runway expected to last until June 2027, but additional capital will be needed to complete pivotal trials and advance pipeline.
Focus on initiating pivotal Phase 3 trial for VT-1953 in 2026 and advancing VT-1908 into clinical development.
Plans to seek further partnerships, licensing, and strategic alliances to support commercialization and development.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Vyome
- Shareholders will vote on directors, an equity plan, auditor ratification, and executive pay.HIND
Proxy Filing15 Dec 2025 - Approval sought for reverse split, warrant exercise, and ELOC share issuance to support merger.HINDProxy Filing15 Dec 2025
- Shareholders to vote on reverse split, warrant exercise, and ELOC issuance to support listing and capital needs.HINDProxy Filing15 Dec 2025
- Shareholders to vote on reverse split, warrant exercise, and ELOC share issuance for Nasdaq compliance.HINDProxy Filing15 Dec 2025
- $5.7M cash, $9.2M net loss, positive VT-1953 data, and 2026 regulatory plans for VT-1908.HINDQ3 202520 Nov 2025
Next Vyome earnings date
Q1 20263 Jun, 2026
Vyome
Next Vyome earnings date
Q1 20263 Jun, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage